<br>        Inclusion criteria:<br><br>          -  Adult patients (=18 years old) with advanced hematological malignancies who relapsed<br>             after or are refractory to standard therapy, or for which no standard therapy existed;<br>             or, were considered inappropriate candidates for standard therapy<br><br>          -  World Health Organization (WHO) performance status = 2<br><br>          -  Patients who met protocol-specified hematologic and non-hematologic laboratory values<br><br>          -  Patients with adequate liver and renal function<br><br>        Exclusion criteria:<br><br>          -  Concurrent brain metastases or leukemic infiltration of the cerebrospinal fluid<br><br>          -  Peripheral neuropathy = CTCAE grade 2<br><br>          -  Unresolved diarrhea = CTCAE grade 2<br><br>          -  Concurrent severe and/or uncontrolled medical conditions which could compromise<br>             participation in the study, including impaired heart function or clinically<br>             significant heart disease, and impaired gastrointestinal function or disease that<br>             significantly altered aborption of LBH589<br><br>          -  Female patients who were pregnant or breast feeding<br><br>          -  Patients who were unwilling to use an effective method of birth control<br><br>          -  Patients who took medications specified by the protocol as prohibited for<br>             administration in combination with LBH589<br><br>          -  Patients with another primary malignancy that required active intervention or were<br>             clinically significant<br>      ;<br>        Inclusion criteria:<br><br>          -  Adult patients (=18 years old) with advanced hematological malignancies who relapsed<br>             after or are refractory to standard therapy, or for which no standard therapy existed;<br>             or, were considered inappropriate candidates for standard therapy<br><br>          -  World Health Organization (WHO) performance status = 2<br><br>          -  Patients who met protocol-specified hematologic and non-hematologic laboratory values<br><br>          -  Patients with adequate liver and renal function<br><br>        Exclusion criteria:<br><br>          -  Concurrent brain metastases or leukemic infiltration of the cerebrospinal fluid<br><br>          -  Peripheral neuropathy = CTCAE grade 2<br><br>          -  Unresolved diarrhea = CTCAE grade 2<br><br>          -  Concurrent severe and/or uncontrolled medical conditions which could compromise<br>             participation in the study, including impaired heart function or clinically<br>             significant heart disease, and impaired gastrointestinal function or disease that<br>             significantly altered aborption of LBH589<br><br>          -  Female patients who were pregnant or breast feeding<br><br>          -  Patients who were unwilling to use an effective method of birth control<br><br>          -  Patients who took medications specified by the protocol as prohibited for<br>             administration in combination with LBH589<br><br>          -  Patients with another primary malignancy that required active intervention or were<br>             clinically significant<br>      ;<br>        Inclusion criteria:<br><br>          -  Adult patients (=18 years old) with advanced hematological malignancies who relapsed<br>             after or are refractory to standard therapy, or for which no standard therapy existed;<br>             or, were considered inappropriate candidates for standard therapy<br><br>          -  World Health Organization (WHO) performance status = 2<br><br>          -  Patients who met protocol-specified hematologic and non-hematologic laboratory values<br><br>          -  Patients with adequate liver and renal function<br><br>        Exclusion criteria:<br><br>          -  Concurrent brain metastases or leukemic infiltration of the cerebrospinal fluid<br><br>          -  Peripheral neuropathy = CTCAE grade 2<br><br>          -  Unresolved diarrhea = CTCAE grade 2<br><br>          -  Concurrent severe and/or uncontrolled medical conditions which could compromise<br>             participation in the study, including impaired heart function or clinically<br>             significant heart disease, and impaired gastrointestinal function or disease that<br>             significantly altered aborption of LBH589<br><br>          -  Female patients who were pregnant or breast feeding<br><br>          -  Patients who were unwilling to use an effective method of birth control<br><br>          -  Patients who took medications specified by the protocol as prohibited for<br>             administration in combination with LBH589<br><br>          -  Patients with another primary malignancy that required active intervention or were<br>             clinically significant<br>      ;<br>        Inclusion criteria:<br><br>          -  Adult patients (=18 years old) with advanced hematological malignancies who relapsed<br>             after or are refractory to standard therapy, or for which no standard therapy existed;<br>             or, were considered inappropriate candidates for standard therapy<br><br>          -  World Health Organization (WHO) performance status = 2<br><br>          -  Patients who met protocol-specified hematologic and non-hematologic laboratory values<br><br>          -  Patients with adequate liver and renal function<br><br>        Exclusion criteria:<br><br>          -  Concurrent brain metastases or leukemic infiltration of the cerebrospinal fluid<br><br>          -  Peripheral neuropathy = CTCAE grade 2<br><br>          -  Unresolved diarrhea = CTCAE grade 2<br><br>          -  Concurrent severe and/or uncontrolled medical conditions which could compromise<br>             participation in the study, including impaired heart function or clinically<br>             significant heart disease, and impaired gastrointestinal function or disease that<br>             significantly altered aborption of LBH589<br><br>          -  Female patients who were pregnant or breast feeding<br><br>          -  Patients who were unwilling to use an effective method of birth control<br><br>          -  Patients who took medications specified by the protocol as prohibited for<br>             administration in combination with LBH589<br><br>          -  Patients with another primary malignancy that required active intervention or were<br>             clinically significant<br>